TC
SGMO

TwinBeech Capital’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

TwinBeech Capital’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-34,466
Closed -$413K – 740
2021
Q2 		$413K Buy
+34,466
New +$390K 0.05% 332
2020
Q4 		– Sell
-23,456
Closed -$222K – 593
2020
Q3 		$222K Buy
+23,456
New +$254K 0.05% 381

Other funds holding SGMO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

TwinBeech Capital's SGMO Position: Q3 2021 in Review

TwinBeech Capital sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q3 2021, closing a stake of 34,466 shares — an estimated $413K sold.

TwinBeech Capital first reported a position in SGMO in Q3 2020 and held it in 2 quarters. The position peaked at $413K in Q2 2021. 193 funds tracked by Wall St. Rank hold SGMO as of Q3 2021.

  • TwinBeech Capital reported no remaining SANGAMO THERAPEUTICS INC position as of Q3 2021 after selling out during the quarter.
  • TwinBeech Capital sold 34,466 SANGAMO THERAPEUTICS INC shares in Q3 2021, an estimated $413K.
  • TwinBeech Capital first reported a position in SANGAMO THERAPEUTICS INC in Q3 2020 and held it in 2 quarters.
  • TwinBeech Capital's SANGAMO THERAPEUTICS INC position peaked at $413K in Q2 2021.
  • 193 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q3 2021.

Based on TwinBeech Capital's 13F filing for Q3 2021, filed 15 Nov 2021.